19125-34-9

Usage

Uses

Used in Pharmaceutical Industry:
1-N-PHENYL-PIPERIDIN-4-ONE is used as a reagent for the preparation of isoteric N-arylpiperazine derivatives. These derivatives are known as dihydropyridine NPY1 receptor antagonists, which play a significant role in the development of medications for various therapeutic applications.
In the context of the provided materials, 1-N-PHENYL-PIPERIDIN-4-ONE is specifically utilized in the synthesis of dihydropyridine NPY1 receptor antagonists. These antagonists are of interest due to their potential applications in treating conditions such as obesity, anxiety, and depression by targeting the neuropeptide Y1 receptor. The compound's unique structure allows for the development of selective and potent antagonists, which can be further optimized for improved pharmacological properties and therapeutic efficacy.

InChI:InChI=1/C11H13NO/c13-11-8-4-5-9-12(11)10-6-2-1-3-7-10/h1-3,6-7H,4-5,8-9H2

Upstream product

• 92246-21-4 4-oxo-1-phenyl-piperidine-3-carboxylic acid ethyl ester 
• 3592-25-4 1,5-dichloropentan-3-one 
• 62-53-3 aniline 
• 188252-72-4 1-Phenyl-4,4-dimethoxypiperidine 
• 117896-69-2 1-phenyl-4-hydroxypiperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 198649-62-6 8-phenyl-1,4-dioxa-8-azaspiro[4,5]decane 
• 140200-76-6 α,α'-dibromopentan-3-one 
• 7564-64-9 3-methyl-1,3,5-pentanetriol 
• 108-86-1 bromobenzene 
• 591-50-4 iodobenzene 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 77542-27-9 1-benzyl-1-methyl-4-oxopiperidin-1-ium iodide salt 
• 170011-70-8 1-(4-amino-phenyl)-piperidin-4-one 

Downstream Products

• 18158-68-4 N,N-di(prop-2-yn-1-yl)aniline 
• 125138-05-8 1-phenyl-4-<(p-cyanophenyl)methylene>piperidine 
• 125138-06-9 1-phenyl-4-(1-naphthylmethylene)piperidine 
• 91759-52-3 4-<(1-Phenyl-4-piperidinylidene)methyl>-1-naphthalenecarbonitrile 
• 125138-09-2 1-phenyl-4-<(pentafluorophenyl)methylene>piperidine 
• 125138-10-5 1-phenyl-4-<<3,5-bis(trifluoromethyl)phenyl>methylene>piperidine 
• 111153-74-3 4-formyl-1-phenylpiperidine 
• 91759-51-2 1-phenyl-4-<(2-naphthyl)methylene>piperidine 
• 112166-49-1 N-Phenyl-4-azacyclohexylidenemalononitrile 
• 125138-03-6 1-Phenyl-4-<methylene>piperidine 
• 7402-94-0 1-phenyl-piperidin-4-one oxime 
• 164299-22-3 4-(1-phenyl-piperidin-4-ylidenemethyl)-benzoic acid methyl ester 
• 188252-72-4 1-Phenyl-4,4-dimethoxypiperidine 
• 299158-67-1 9-(1-Phenyl-4-hydroxypiperidin-4-yl)-3,3-dimethyl-1,5-dioxaspiro[5.5]undecane-9-carboxylic acid 

Relevant academic research and scientific papers

Synthesis method of intermediate N-phenyl-4-piperidone

The invention discloses a synthesis method of an intermediate N-phenyl-4-piperidone, which comprises the following steps: dissolving aniline in diethyl ether, adding a catalyst, adding 3-methyl-1,3,5-pentanetriol under stirring, heating the raw material t

Dual C(sp3)?H Bond Functionalization of N-Heterocycles through Sequential Visible-Light Photocatalyzed Dehydrogenation/[2+2] Cycloaddition Reactions

Herein we describe a mild method for the dual C(sp3)?H bond functionalization of saturated nitrogen-containing heterocycles through a sequential visible-light photocatalyzed dehydrogenation/[2+2] cycloaddition procedure. As a complementary approach to the well-established use of iminium ion and α-amino radical intermediates, the elusive cyclic enamine intermediates were effectively generated by photoredox catalysis under mild conditions and efficiently captured by acetylene esters to form a wide array of bicyclic amino acid derivatives, thus enabling the simultaneous functionalization of two vicinal C(sp3)?H bonds.

NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES

Disclosed herein are 5 or 8-substituted imidazo [1, 5-a] pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo [1, 5-a] pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo [1, 5-a] pyridines that can be useful for inhibiting indoleamine 2, 3-dioxygenase and/or tryptophane 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents

Synthesis and biological evaluation of a novel library of fused 1,2,3-triazole derivatives are described. The in-house developed multicomponent reaction based on commercially available starting materials was applied and broad biological screening against various viruses was performed, showing promising antiviral properties for compounds 14d, 14n, 14q, 18f and 18i against human coronavirus 229E. Further in silico studies identified the key molecular interactions between those compounds and the 3-chymotrypsin-like protease, which is essential to the intracellular replication of the virus, supporting the hypothesis that the protease is the target molecule of the potential antiviral derivatives.

Fused tricyclic hepatitis virus inhibitor and application thereof

The invention belongs to the field of medical chemistry, relates to a fused tricyclic hepatitis virus inhibitor and application thereof, and particularly, provides a compound of the general formula I or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and a medicine composition containing the compounds and application of the compounds or the composition in medicine preparation. The compound has the good inhibiting activity on hepatitis C virus, meanwhile has the low toxicity on host cells, and is high in effectiveness, good in safety and likely to become the medicine for treating and/or preventing diseases relevant to HCV infection.

UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS

There is provided a compound having Formula I:(I) wherein: R1 is aryl which is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy, or R1 is aryl which is substituted with a second aryl group or an aryloxy group, wherein the second aryl group or the aryloxy group is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy; R2 is C1-4 alkyl; R3 is selected from hydroxyl and OSO2CH3; R4 and R5 are independently selected from hydrogen, hydroxyl and halogen; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; wherein when R3 is hydroxyl and R4 and R5 are not hydroxyl, the optionally substituted aryl group, second aryl group or aryloxy group of R1 is substituted with one or more hydroxyl groups or C1-4 alkoxy groups, or wherein when R3 is hydroxyl, one of R4 and R5 is hydroxyl, provided that the compound is not N-(1-benzylpiperidin-4-yl)-4-(3,4-dihydroxyphenyl)-N-methyl-1H-imidazole-1-carboxamide hydrobromide. The compound may be used as an inhibitor of fatty acid amide hydrolase.

UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS

A compound having Formula (I): wherein: R1 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R3 is C1-4 alkyl; R4 is aryl which is substituted with a group selected from OSO2NH2, NHCONH2, NHSO2NH2, NHSO2C1-4 alkyl and CONH2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methylsulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.

COMPOUNDS AND METHODS

Disclosed are compounds having formula I, wherein X1, X2, X3, R1, R2, R3, R4, R5, Y, A, Z, L, m and n are as defined herein, and methods of making and using the same.

5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND

The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided: [wherein, R1 represents a group —X-Q1, X-Q1-Y-Q2 or X-Q1-Y-Q2-Z-Q3, X represents a single bond, —CH2— or the like, Q1 represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH2—, or the like, Q2 represents a monocyclic or bicyclic hydrocarbon ring group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), Z represents a single bond, —CR11R12— or the like, R11 and R12 each independently represents a hydrogen atom, a halogen atom or the like, Q3 represents a phenyl group which may have substituent(s), a C3-C7 cycloalkyl group which may have substituent(s), a C3-C7 cycloalkenyl group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), R2 represents a C1-C3 alkyl group or the like, and R3 represents a hydrogen atom or a methyl group].

2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.